Special Drug Use-results Surveillance of Tabrecta Tablets

Overview

This study is an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study will collect all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient is up to 1 year (52 weeks)

Full Title of Study: “Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 31, 2024

Interventions

  • Drug: Tabrecta tablets
    • There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.

Arms, Groups and Cohorts

  • Tabrecta tablets
    • Patients administered Tabrecta by prescription

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients with adverse reactions
    • Time Frame: 1 year
    • An adverse reaction is defined as an adverse event that is suspected by the investigator to be causally related to Tabrecta or whose causality is not recorded.
  • Response rate
    • Time Frame: 1 year
    • A response rate is defined as a proportion of patients whose best overall response is CR or PR as assessed by the RECIST version 1.1(Eisenhauer et al. 2009). Patients assessed as not evaluable (NE) will be handled as non-responders, and included in the denominator for the calculation of response rates.
  • Overall survival rate
    • Time Frame: 1 year
    • The Kaplan-Meier method will be used to estimate the survival curve. Overall survival is defined as the duration from the start date of Tabrecta administration to death of any cause. For patients surviving to the end, OS will be censored at the end date of the observation period.
  • Progression-free survival (PFS)
    • Time Frame: 1 year
    • the Kaplan-Meier method will be used to estimate the PFS curve according to RECIST version 1.1 (Eisenhauer et al. 2009). PFS is defined as the duration from the start date of Tabrecta administration to the date of the date of the first PD observed or death of any cause, whichever comes first. For patients without these events, PFS will be censored at the end date of the observation period.

Participating in This Clinical Trial

Inclusion Criteria

  • All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period Exclusion Criteria:

-

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Novartis Pharmaceuticals, Study Director, Novartis Pharmaceuticals
  • Overall Contact(s)
    • Novartis Pharmaceuticals, +81337978748, novartis.email@novartis.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.